Search
for
Sort by
Research 571–600 of 1000+
- A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Comparison of efficacy of platelet-rich plasma therapy with or without topical 5% minoxidil in male-type baldness: A randomized, double-blind placebo control trial
- A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome
- A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition, and Metabolic Profile in Transmen
- A Randomized Placebo-Controlled Multicentre Study to Evaluate the Safety and Efficacy of Finasteride for Male Chronic Pelvic Pain Syndrome (Category IIIA Chronic Nonbacterial Prostatitis)
- Commentary on a Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia
- P‐46 A placebo‐controlled, double‐blinded study of recombinant IFNγ in dogs with atopic dermatitis
- The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
- A Double Blind Randomized Placebo Controlled Clinical Trial of Finasteride in the Treatment of Androgenetic Alopecia
- Capryloyl glycine and soy isoflavonoids in hypertrichosis: An experimental and placebo‐controlled clinical study
- Blinding in Placebo-Controlled Trials
- Open-label placebos reduce hair cortisol concentrations and psychological distress - a randomized controlled trial
- Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
- Treatment of refractory hematospermia with Finasteride: A prospective placebo-controlled study
- A randomized double-blind placebo-controlled clinical trial to evaluate the effect of an Annurca apple supplement formula in androgenic alopecia
- Blinding in Placebo-Controlled Trials
- Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo‐controlled study
- A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Finasteride for treatment of refractory hemospermia: prospective placebo-controlled study
- Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- Review of the Literature: A Placebo Controlled Split Scalp Study of PRP for Male Pattern Baldness
- How does topical minoxidil compare with placebo for treating female pattern hair loss?
- Faculty Opinions recommendation of Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia.
- A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia